<DOC>
	<DOCNO>NCT02000531</DOCNO>
	<brief_summary>This trial extension ENSURE , study erlotinib versus gemcitabine/cisplatin combination chemotherapy first-line treatment patient non-small-cell lung cancer ( NSCLC ) mutation tyrosine kinase domain EGFR . This study design examine efficacy erlotinib versus gemcitabine/cisplatin second-line treatment NSCLC patient ENSURE trial ( NCT01342965 ) . Patients previously treat gemcitabine/cisplatin give erlotinib daily disease progression unacceptable toxicity occurs . Patients previously treat erlotinib give cisplatin Day 1 gemcitabine Days 1 8 3-week chemotherapy cycle disease progression , unacceptable toxicity 4 cycle ( whichever come first ) .</brief_summary>
	<brief_title>Progression Free Survival ( PFS ) Using Erlotinib Non-Small-Cell Lung Cancer ( NSCLC ) Chinese Population</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Participant ENSURE trial Disease progression firstline treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Non-small-cell lung cancer ( NSCLC )</keyword>
</DOC>